FDA Approves MannKind’s Afrezza for Pediatric Diabetes, Expanding Market Reach
Event summary
- FDA approves Afrezza® for children and adolescents aged 6+ with diabetes, expanding its use beyond adults.
- Approval supported by Phase 3 INHALE-1 study and 20+ years of clinical data on Technosphere® inhaled insulin.
- Afrezza available for $35 or less per month, with support through MannKind Cares.
- First inhaled mealtime insulin option recognized in ADA Standards of Care alongside MDI and insulin pumps.
The big picture
MannKind’s FDA approval for Afrezza in pediatric diabetes marks a strategic pivot into a high-need market segment, addressing the challenges of mealtime insulin management for children. The approval aligns with broader industry trends toward patient-centric, non-invasive treatments, potentially reshaping the competitive landscape for diabetes care. With over 350,000 children in the U.S. living with diabetes, this expansion could significantly boost MannKind’s revenue and market positioning.
What we're watching
- Market Adoption
- How quickly Afrezza gains traction among pediatric patients and caregivers, given its needle-free convenience.
- Competitive Dynamics
- Whether MannKind can sustain differentiation against traditional insulin delivery methods like pumps and injections.
- Regulatory Compliance
- The pace at which MannKind addresses potential lung-related safety concerns, given Afrezza’s inhaled delivery mechanism.